Skip to main content
Erschienen in: Journal of Radiation Oncology 3/2018

08.05.2018 | Original Research

The albumin-bilirubin (ALBI) model in hepatocellular carcinoma (HCC) may better predict hepatic failure in patients with traditionally low-risk cirrhosis following definitive stereotactic body radiotherapy (SBRT)

verfasst von: S. Hasan, Stephen Abel, Imraan Jan, Tadahiro Uemura, N. Thai, A. V. Kirichenko

Erschienen in: Journal of Radiation Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

Stereotactic body radiotherapy (SBRT) in hepatocellular carcinoma (HCC) is safe and effective in Child Pugh (CP) A cirrhosis, though a subset of patients may be at higher risk for progressive liver failure. The albumin-bilirubin (ALBI) model is a simple, novel, and validated prognostic assessment of hepatic cirrhosis in patients with HCC, but its utilization during liver SBRT is not well studied. Compared to conventional stratifications of cirrhosis, we hypothesize that the ALBI model is a sensitive predictor of hepatic function, survival, and liver failure following definitive SBRT for HCC in patients with CP-A cirrhosis.

Methods

From 2009 to 2016, 40 patients with HCC and CP-A cirrhosis completed SBRT. The mean dose was 45 Gy (40 to 50 Gy) in 4–5 fractions. Local control defined as the absence of tumor progression was assessed with CT or MRI every 3–6 months after SBRT. ALBI, MELD (model of end stage liver disease), and CP scores were recorded before treatment and every 3–4 months after. ALBI scores were calculated from the formula (log(bilirubin[mcmol/L]) × 0.66) − (albumin[g/L] × 0.085) and classified as ALBI-1, ALBI-2, or ALBI-3. Initial scores were measured against progression to CP-B cirrhosis and survival. Kaplan-Meier statistical analysis was conducted via MedCalc software.

Results

Forty patients with 49 HCC lesions were analyzed in this IRB approved retrospective study. Median tumor diameter was 3.5 cm (1.4–8.9 cm). Eight patients underwent orthotropic liver transplant (median time to transplant was 12 months). Prior to SBRT, 17 patients had ALBI-1 and 23 had ALBI-2 scores.The actuarial local control at 2 years was 98%. With the median follow-up of 23.4 months, overall survival (OS) was 92 and 60% at 1 and 2 years. Freedom from progression to CP-B was 74 and 62% at 1 and 2 years. Compared to pre-treatment ALBI-2 patients, ALBI-1 patients correlated with higher freedom from CP progression (HR = 3.66, P = 0.03), but not OS (P = 0.09). At the last follow-up, 22 of 40 patients (55%) progressed to a higher ALBI grade (12 from ALBI-1 to 2 and 10 from ALBI-2 to ALBI-3). The 2-year OS for patients with an ALBI-1 (n = 5), ALBI-2 (n = 25), and ALBI-3 (n = 10) at last follow-up was 80, 74, and 30%, respectively (P = 0.03).

Conclusion

Our study indicates that the ALBI index more precisely predicted liver failure and survival in HCC following SBRT compared to CP scoring. Its application may help select the most ideal candidates for SBRT among the often heterogeneous CP-A population. Further study regarding precautionary measures such as functional treatment planning for ALBI-2 patients treated with liver SBRT may be warranted.
Literatur
1.
Zurück zum Zitat El-Serag HB, Kanwal F (2014) Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 60:1767–1775CrossRef El-Serag HB, Kanwal F (2014) Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 60:1767–1775CrossRef
2.
Zurück zum Zitat Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338CrossRef Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338CrossRef
3.
Zurück zum Zitat Citterio D, Facciorusso A, Sposito C, Rota R, Bhoori S, Mazzaferro V (2016) Hierarchic interaction of factors associated with liver decompensation after resection for hepatocellular carcinoma. JAMA Surg 151:846–853CrossRef Citterio D, Facciorusso A, Sposito C, Rota R, Bhoori S, Mazzaferro V (2016) Hierarchic interaction of factors associated with liver decompensation after resection for hepatocellular carcinoma. JAMA Surg 151:846–853CrossRef
4.
Zurück zum Zitat Child CG (1964) Remote results of portal surgery in liver cirrhosis. Rev Int Hepatol 14:287–288PubMed Child CG (1964) Remote results of portal surgery in liver cirrhosis. Rev Int Hepatol 14:287–288PubMed
5.
Zurück zum Zitat D'Amico G, Garcia-Tsao G, Pagliaro L (2006) Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44:217–231CrossRef D'Amico G, Garcia-Tsao G, Pagliaro L (2006) Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44:217–231CrossRef
6.
Zurück zum Zitat Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 31:1631–1639CrossRef Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 31:1631–1639CrossRef
7.
Zurück zum Zitat Cardenes HR, Price TR, Perkins SM et al (2010) Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol: Off Publ Fed Spanish Oncol Soc Natl Canc Inst Mexico 12:218–225CrossRef Cardenes HR, Price TR, Perkins SM et al (2010) Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol: Off Publ Fed Spanish Oncol Soc Natl Canc Inst Mexico 12:218–225CrossRef
8.
Zurück zum Zitat Mendez Romero A, Wunderink W, Hussain SM et al (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol 45:831–837CrossRef Mendez Romero A, Wunderink W, Hussain SM et al (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol 45:831–837CrossRef
9.
Zurück zum Zitat Lasley FD, Mannina EM, Johnson CS, Perkins SM, Althouse S, Maluccio M, Kwo P, Cárdenes H (2015) Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol 5:e443–e449CrossRef Lasley FD, Mannina EM, Johnson CS, Perkins SM, Althouse S, Maluccio M, Kwo P, Cárdenes H (2015) Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol 5:e443–e449CrossRef
10.
Zurück zum Zitat Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol : Off J Am Soc Clin Oncol 33:550–558CrossRef Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol : Off J Am Soc Clin Oncol 33:550–558CrossRef
11.
Zurück zum Zitat Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H, Kaneto M, Aibiki T, Okudaira T, Kawakami T, Kawamura T, Yamago H, Suga Y, Miyamoto Y, Tomida H, Azemoto N, Mori K, Miyata H, Ninomiya T, Kawasaki H (2016) Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol 31:1031–1036CrossRef Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H, Kaneto M, Aibiki T, Okudaira T, Kawakami T, Kawamura T, Yamago H, Suga Y, Miyamoto Y, Tomida H, Azemoto N, Mori K, Miyata H, Ninomiya T, Kawasaki H (2016) Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol 31:1031–1036CrossRef
12.
Zurück zum Zitat Kirichenko A, Gayou O, Parda D, Kudithipudi V, Tom K, Khan A, Abrams P, Szramowski M, Oliva J, Monga D, Raj M, Thai N (2016) Stereotactic body radiotherapy (SBRT) with or without surgery for primary and metastatic liver tumors. HPB: Off J Int Hepato Pancreato Biliary Assoc 18:88–97CrossRef Kirichenko A, Gayou O, Parda D, Kudithipudi V, Tom K, Khan A, Abrams P, Szramowski M, Oliva J, Monga D, Raj M, Thai N (2016) Stereotactic body radiotherapy (SBRT) with or without surgery for primary and metastatic liver tumors. HPB: Off J Int Hepato Pancreato Biliary Assoc 18:88–97CrossRef
13.
Zurück zum Zitat Gayou O, Day E, Mohammadi S, Kirichenko A (2012) A method for registration of single photon emission computed tomography (SPECT) and computed tomography (CT) images for liver stereotactic radiotherapy (SRT). Med Phys 39:7398–7401CrossRef Gayou O, Day E, Mohammadi S, Kirichenko A (2012) A method for registration of single photon emission computed tomography (SPECT) and computed tomography (CT) images for liver stereotactic radiotherapy (SRT). Med Phys 39:7398–7401CrossRef
14.
Zurück zum Zitat Hasan STN, Uemura T, Kudithipudi V, Renz P, Abel S, Kirichenko AV (2017) Hepatocellular carcinoma with Child Pugh-A cirrhosis treated with stereotactic body radiotherapy. World J Gastrointes Surg 9:256–263CrossRef Hasan STN, Uemura T, Kudithipudi V, Renz P, Abel S, Kirichenko AV (2017) Hepatocellular carcinoma with Child Pugh-A cirrhosis treated with stereotactic body radiotherapy. World J Gastrointes Surg 9:256–263CrossRef
15.
Zurück zum Zitat Toesca DAS, Osmundson EC, von Eyben R, Shaffer JL, Koong AC, Chang DT (2017) Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer. Pract Radiat Oncol 7:173–182CrossRef Toesca DAS, Osmundson EC, von Eyben R, Shaffer JL, Koong AC, Chang DT (2017) Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer. Pract Radiat Oncol 7:173–182CrossRef
16.
Zurück zum Zitat Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol: Off J Am Soc Clin Oncol 27:1572–1578CrossRef Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol: Off J Am Soc Clin Oncol 27:1572–1578CrossRef
17.
Zurück zum Zitat Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC, Fisher GA, Koong AC (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78:486–493CrossRef Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC, Fisher GA, Koong AC (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78:486–493CrossRef
18.
Zurück zum Zitat Kudithipudi V, Day E, Thai N et al (2017) Liver stereotactic radiotherapy (SRT) with functional treatment planning for patients with intermediate stage hepatocellular carcinoma (HCC). J Radiat Oncol 6:371–377CrossRef Kudithipudi V, Day E, Thai N et al (2017) Liver stereotactic radiotherapy (SRT) with functional treatment planning for patients with intermediate stage hepatocellular carcinoma (HCC). J Radiat Oncol 6:371–377CrossRef
19.
Zurück zum Zitat Xu ZY, Liang SX, Zhu J, Zhu XD, Zhao JD, Lu HJ, Yang YL, Chen L, Wang AY, Fu XL, Jiang GL (2006) Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys 65:189–195CrossRef Xu ZY, Liang SX, Zhu J, Zhu XD, Zhao JD, Lu HJ, Yang YL, Chen L, Wang AY, Fu XL, Jiang GL (2006) Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys 65:189–195CrossRef
20.
Zurück zum Zitat Fleming KM, Aithal GP, Card TR, West J (2012) All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int: Off J Int Ass Stud Liver 32:79–84CrossRef Fleming KM, Aithal GP, Card TR, West J (2012) All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int: Off J Int Ass Stud Liver 32:79–84CrossRef
21.
Zurück zum Zitat Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol : Off J Am Soc Clin Oncol 26:657–664CrossRef Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol : Off J Am Soc Clin Oncol 26:657–664CrossRef
Metadaten
Titel
The albumin-bilirubin (ALBI) model in hepatocellular carcinoma (HCC) may better predict hepatic failure in patients with traditionally low-risk cirrhosis following definitive stereotactic body radiotherapy (SBRT)
verfasst von
S. Hasan
Stephen Abel
Imraan Jan
Tadahiro Uemura
N. Thai
A. V. Kirichenko
Publikationsdatum
08.05.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Radiation Oncology / Ausgabe 3/2018
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-018-0354-7

Weitere Artikel der Ausgabe 3/2018

Journal of Radiation Oncology 3/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.